THE ACTO TIMES: 2026 New Year EDITION

Dear readers and friends of The ACTO Times,

As we welcome the New Year 2026, I would like to extend my warmest greetings and sincere appreciation to everyone who has supported The ACTO Times. Your continued engagement through reading, submitting manuscripts, reviewing, and sharing our work has been essential to our progress and momentum.

As Editor-in-Chief, I am thrilled to share one of our most meaningful milestones: The ACTO Times has been granted an ISSN (3105-6539). This achievement strengthens the journal’s identity and visibility and marks an important step toward our long-term development and international recognition.

We are also encouraged by the continued growth in readership. Under the leadership of Chairperson Professor Shimosaka and the Advisory Board, our latest readership and website traffic report shows steady increases in visits and engagement.

This reflects rising interest in the topics we publish and the value our community finds in the journal. We are grateful for this trust, and we will continue to enhance the quality, relevance, and accessibility of our content.

In 2026, we are pleased to welcome new leadership and expertise to our team. We are honored to introduce Professor Kenneth Kaushansky, MD, MACP, as a new member of our Editorial Advisory Board. He is Dean and Distinguished Professor Emeritus of the Renaissance School of Medicine at Stony Brook University and the former Editor-in-Chief of Blood. We are also delighted to welcome Dr. WH Chen, President of the Taiwan Association of Cellular Therapy (TACT), as our new Vice President in Taipei. Their experience, insight, and commitment will further strengthen our editorial direction and expand our academic and professional network.

In this New Year 2026 edition, The ACTO Times is pleased to present special highlights that reflect both important policy progress and regional scientific collaboration. We feature timely perspectives on Taiwan’s Regenerative Medicine Act, focusing on its significance for clinical translation, regulatory readiness, and the future development of regenerative therapies in Taiwan. We also highlight ACTO Indonesia 2026 as a key platform for exchange and partnership across Asia, and we look forward to sharing emerging research, strengthening cross-border collaboration, and advancing shared standards and innovation in the field.

Looking ahead, 2026 will be a year of continued progress and innovation for The ACTO Times. We will further expand our academic scope and strengthen our publishing practices, with particular attention to emerging directions such as AI and cell and gene therapy (CGT). We also look forward to engaging with the broader community at ACTO Indonesia 2026, where we hope to build closer collaborations across Asia.

Thank you again for being part of The ACTO Times community. We look forward to working together with all of you.

With best wishes for a successful and inspiring 2026,

Sincerely,

Yen Hua Huang, PhD  

Distinguished Professor, Taipei Medical University  

Editor-in-Chief, The ACTO Times  

ACTO, Asian Cellular Therapy Organization